Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315425 | 0.94 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL16415290 | 0.94 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL25313896 | 0.94 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL26654990 | 0.93 | GPR119 (0.56) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL8651411 | 0.93 | GPR119 (0.67) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL31683631 | 0.92 | GPR119 (0.67) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL31746376 | 0.91 | GPR119 (0.68) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL22032226 | 0.91 | GPR119 (0.68) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL21758110 | 0.90 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL4828186 | 0.89 | GPR119 (0.47) | GPR119MMP13KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV DUNDEE (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658658-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-09-11 | — | — | US | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002092577-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092578-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | GPR119 4442/4885MMP13 1726/4885KMT2A 1520/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GPR119 4238/4885MMP13 2128/4885KMT2A 1723/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | GPR119 2252/4885MMP13 1835/4885KMT2A 257/4885 |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | VHL, HMBS, BRCA1 | GPR119 2605/4885MMP13 399/4885KMT2A 1143/4885 |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | SRR, SRRM2, CRBN | GPR119 2508/4885MMP13 1665/4885KMT2A 2615/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | GPR119 1311/4885MMP13 2214/4885KMT2A 2454/4885 |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | LRRK2, XIAP, PARK7 | GPR119 3041/4885MMP13 1949/4885KMT2A 2247/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | GPR119 344/4885MMP13 3473/4885KMT2A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.